Atlas Trials

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Clinical trial NCT05171777 · COMPLETED

Trial details

NCT number
NCT05171777
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2022-04-04
Primary completion
2023-11-09
Enrollment
179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.